Pharmacy Compounding: Infection Prevention

Similar documents
Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey

Sterile Compounding elearning Course Curriculum 28 lessons with 33 hours of CE. Fundamentals of Sterile Compounding (8 lessons/8 hours CE)

USP <800> A practical approach to compliance. Ryan W. Naseman, PharmD, MS, BCPS Michael Storey, PharmD, MS, BCPS

LUNCH AND LEARN. October 14, CE Activity Information & Accreditation

History and Update of Chapters 797 and 800

USP<797> AND THE ASEPTIC PROCESSING OF RADIOPHARMACEUTICALS PART 1

BRIEFING 797 PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS INTRODUCTION

Ensuring Quality Pharmacy Compounding: Implications for Pharmaceutics Education

Compounding nonsterile preparations: USP <795> and <800>

Study Summary. Results: All tested media-filled vials were negative for growth of any microorganisms.

á797ñ PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS

US Regulatory Requirements: Clinical & Clinical Research Production, SPECT & PET Radiopharmaceuticals (RPs)

USP <797> and Environmental Sampling

Pharmacy Quality Assurance Commission Sterile Compounding [USP <797>] Self-Assessment Compliance Checklist

Chapter WAC Compounding Practices Crosswalk

Where Quality Meets Flexibility

Overview. A brief from

USP <797> Compliance Common Challenges and Potential Solutions

Profiles in CSP Insourcing: Scripps Health

Inspection Form. DPP Information. Inspection Information. Staff Information. Service Information. DPP Designated Member. Street City Postal Code

The GAP Analysis for Nonsterile Compounding

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Facility Design for Pharmacy Operation. Full-Scale Nuclear. Slides are not to be reproduced without permission of author.

Thanks and acknowledgement to Pamela Isaacs for the content and slides in this presentation.

Latest USP Initiatives: Monographs, General Chapters, and Compounding

MINIMUM REQUIREMENTS FOR A VENDOR

Guidelines for Design of. Compounded Sterile Products (CSPs) Facility

FDA Update on Compounding

BD Cato. medication workflow solutions. Elevating the standard of IV compounding

Quality is Our Promise.

Secundum Artem. USP Chapter <795> Pharmaceutical Compounding - Nonsterile Preparations INTRODUCTION BACKGROUND VOLUME 13 NUMBER 4

Microbiological Consideration for Non-Sterile Pharmaceutical

UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS

Meeting of the Minds: Pharmacy Services and Integration

FLORIDA SOCIETY OF HEALTH SYSTEM PHARMACISTS NOVEMBER 4, 2016 JAMES T WAGNER CONTROLLED ENVIRONMENT CONSULTING

TITLE: Research Pharmacy Standard Policy SOP #: INV-100 Page: 1 of 5 Effective Date: 8/31/17

Barcodes on Unit of Use

HardyVal TM CSP MEDIUM-RISK LEVEL MEDIA-FILL CHALLENGE KITS

Latest Developments in USP Monographs and the Compounding of Sterile Radiopharmaceuticals. Jim Ponto, MS, RPh, BCNP

2008 ASHP Summer Meeting Seattle, Washington Educational Session Abstracts

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC

HEALTHCARE. BoxPicker Automated Pharmacy Storage System

Orange and Yellow Guides

for IND and RDRC Regulated PET Compounding

Resolution CM/Res(2016)2 on good reconstitution practices in health care establishments for medicinal products for parenteral use

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

HardyVal TM CSP RANDOM TEST KIT

Full Contact Details:

Responding to an FDA 483

Testosterone 20 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets) Ingredient Listing Qty. Unit NDC # Supplier

Harmonizing FDA Regulation and the Practice of Pharmacy: Challenges and Opportunities. Plus an update on PET Drug User Fees

USP 797 & 800 Pharmacy Overview. (Presented to Vermont Chapter of New England Healthcare Engineers May 2016)

The Current State of Compounding Standards: What Happens Next? Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison NJ

Compounding Aseptic Isolators (CAI) James T Wagner

Environmental Monitoring of Aseptic Processing Areas - 1

FDA s Guidance for Industry

Introduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics

Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco

Caffeine 100 mg, Scopolamine Hydrobromide 0.5 mg Oral Rapid-Dissolve Tablets (Solid Suspension, 96 x 750 mg [0.93 ml] Tablets)

Medication errors: Development of prevention strategies for medicines and medical devices

Compounding Pharmacies and Water

SFHPHARM18 - SQA Unit Code FA2L 04 Prepare aseptic products

Pharmacy. Medication. Checks

National Drug Codes Requirement for UnitedHealthcare Community Plan. Calculating the Appropriate Number of National Drug Code (NDC) Units

CDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA

Auditing Microbiology Media Suppliers

Risk Management in Drug Product Manufacturing with Emphasis on Batch Documentation/Execution

General Good Compounding Practices for Nonsterile Products

GUIDELINE FOR THE STABILITY TESTING

NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

EAHP STATEMENT ON THE NEED FOR BARCODING OF THE SINGLE DOSE ADMINISTERED IN HOSPITALS

Coding Systems Understanding NDC and HCPCS

PhEn-602 Notes # 4 J. Manfredi

Controlled environments

GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH MICHIGAN STATE UNIVERSITY ENVIRONMENTAL HEALTH AND SAFETY

Assessing the management of anti-tb medicines and supplies

BEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development

Porton Biopharma Limited 1/17/17

USP Chapter <797>: De-mystifying Beyond-Use Dating. Eric S. Kastango, MBA, RPh, FASHP Clinical IQ, LLC Florham Park, NJ

Engaging Colleagues: Making Connections to Answer the Insourcing Tough Questions

2008 USPC Official 5/1/08-7/31/08 General Chapters: <797> PHARMACEUTICAL... Page 1 of PHARMACEUTICAL COMPOUNDING STERILE PREPARATIONS

IV solutions that fit

Overview of a sterility assurance program for PET drugs

INVESTIGATIONAL DRUG SERVICE (IDS) Standard Operating Procedures

Under this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at

Pain Full Drug Shortages

Who says you re competent?

Microbiology Research Associates

Key Elements of a Microbial Contamination Control Policy Why and how to write a policy for Microbial Contamination Control

Volunteering for Clinical Trials

USP <797> : IP + Pharmacist as partners in Medication Safety

DRUG ORDERING AND MAINTENANCE

CPPE Leading for change Programme handbook

Emcure Pharmaceuticals Limited 3/3/16

Transcription:

Pharmacy Compounding: Infection Prevention Sam Eberwein, PharmD, MS, BCPS Clinical Manager, Sterile Products Area, Perioperative Services, & Special Formulations UNC Medical Center Department of Pharmacy November 8, 2017

What is compounding?

What is compounding? NC Board of Pharmacy 1» taking two or more ingredients and combining them into a dosage form of a drug, exclusive of compounding by a drug manufacturer, distributor, or packer FDA» combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient 2» Compounding does not include mixing, reconstituting, or similar acts that are performed in accordance with the directions contained in approved labeling provided by the product's manufacturer and other manufacturer directions consistent with that labeling" 3 USP 4» The preparation, mixing, assembling, alterating, packaging, and labeling of a drug or drug-delivery device Specifically includes: Reconstitution or manipulation of commercial products that may require the addition of one or more ingredients. 1. Pharmacy Practice Act, N.C. Gen. Stat. 90-85.3.(c) 2. FDA FAQ on compounding published 10/06/2015 3. [21 USC 321 (k) and (m)]. 4. USP <795> Pharmaceutical Compounding-Nonsterile Preparations

Federal Why do we care? USP Chapters <1000 enforceable FDA currently using Enforcement Discretion State State Boards of Pharmacy can enforce only if FD&C Act is within regulations or if they have adopted its own version The NCBOP has incorporated into its regulations USP 795 and 797 standards (and will include 800)

Why do we care? Scope of applicability Health care organizations Pharmacies Physician practice facilities Any and all facilities where CSPs are prepared, stored, and dispensed The Joint Commission TJC expects compliance. Applies to all personnel who are preparing sterile products that are going to be used but are going to stored until used

CSPs Incidents

Beyond Use Dates What is a Beyond Use Date (BUD)? How does a BUDs compare to: Spike by time Discard after time Expiration date Hang time

USP 795 Risk Categories Categories Description Examples Simple Moderate Complex Compound has a USP monograph or appears in peer-reviewed literature Compound that has special calculations or procedures Compound that requires special training, environment, facility, equipment, or procedures Captopril Oral Solution Morphine sulfate suppositories Transdermal dosage forms

BUD Assignment Non-sterile Categories Nonaqueous formulations Water containing oral formulation Water containing Topical/Dermal and Mucosal Liquid and Semisolid Formulation BUD No later than the expiration of the earliest API or 6 months, whichever is earlier No later than 14 days when stored at controlled room temp No later than 30 days Note: no BUD should never be longer than any ingredient s expiration. Stability data that is longer can override these limits, however microbial growth should be considered.

Sterile compounding - Operational issues Operational Process Training Equipment Environment CSP Preparation Cleaning Personnel

Literature Accuracy/Sterility - Trissel 2003 1 and 2005 2 Estimated microbial contamination for Low and Medium-risk CSPs Evaluated aseptic technique of pharmacists and technicians from 2002-2003 (n=267) - 0.1% contamination for Low-risk CSPs (n=1058) - 5.8% overall contamination rate for Medium-risk CSPs (n=539) - Even worse rate for staff who regularly compounded 1. Am J Health Syst Pharm. 2003; 60:1853-55 2. Am J Health Syst Pharm. 2005; 62:285-288.

2. Put on Hair and Face Covers 3. Put on shoe covers

Environmental quality/control

Environmental quality/control Necessary ISO cleanroom components Airborne particulate count PEC (LAFWs/RABS/Barrier isolators): <ISO Class 5 Buffer zone: <ISO Class 7 Anteroom: <ISO Class 8 Air exchanges >30 exchanges/hour (At least 15 from the PEC) Positive pressure (non-hazardous) At least 0.02-inch water column Materials of construction Limit ledges, crevices, etc. Where is the sink?

Storage and Dating Single-dose vial Opened or needle punctured single-dose >ISO Class 5 used within 1 hour <ISO Class 5 used up to 6 hour period* *(must be continuously exposed)

Storage and Dating Multiple-dose vial Opened or needle punctured multiple-dose 28 days or manufacturer specifications

Microbiological BUD Information resources Chemical stability limits from literature or testing USP Chapter <797> It is your professional obligation to determine the risk level

Putting it all together

Case studies Your hospital has just purchased an ENT clinic and has asked your advice on reducing drug costs for the clinic. At nearly $1000 a vial, the Botox they are using to treat torticollis represents more than half their drug expenditure. Unfortunately, the average dose is only 0.1 ml of the 1 ml vial, leaving most of each vial wasted. In a dramatic cost savings move, a physician who is new to the clinic has started drawing up doses for all of his patients for the day from a single vial. This innovative practice is anticipated to save hundreds of thousands of dollars a year for the clinic. What would you advise the new clinic leadership to do?

Case studies At a clinic visit, a nurse expresses concern that a patient s family is violating USP 797 and asks you to speak with the mother. When asked, the mother describes how she draws up two doses at a time from her son s vial of filgrastim. One dose she gives immediately and the other she stores in the refrigerator for the next day. You know that filgrastim vials are single dose vials and you also know that they are quite expensive and this patient has poor insurance coverage. How do you respond to the nurse s concerns and what do you advise the mother?

Video Tour of Pharmacy

Pharmacy Compounding: Infection Prevention Sam Eberwein, PharmD, MS, BCPS Clinical Manager, Sterile Products Area, Perioperative Services, & Special Formulations UNC Medical Center Department of Pharmacy November 8, 2017